# Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

> **NCT04975997** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 939 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Iberdomide
- **DRUG:** Iberdomide
- **DRUG:** Iberdomide
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04975997
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2027-11-16
- **Final completion:** 2032-06-25
- **Target enrollment:** 939 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975997, "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04975997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*